Infectious Disease Complications: HIV and Hepatitis

Injection drug use and associated risk behaviours create routes for blood-borne pathogens, making HIV and viral hepatitis among the most consequential medical complications of substance use. The intersection of addiction and infection links individual behaviour to population-level transmission and to structural conditions of risk.

Definition

Infectious disease complications of substance use refers to the blood-borne and related infections, chiefly HIV and viral hepatitis, that are transmitted through injection drug use and associated risk behaviours.

Scope

This topic covers the connection between substance use, particularly injection, and the major blood-borne infections (HIV, hepatitis C, and hepatitis B), the behaviours and structures that drive transmission, and the population-level burden among people who inject drugs. It is a reference entry on these infectious complications, not clinical guidance on testing or treatment.

Core questions

• How does injection drug use transmit HIV and viral hepatitis?
• Why are people who inject drugs disproportionately affected by these infections?
• What roles do individual, structural, and combination factors play in transmission and prevention?
• What is the global burden of HIV, hepatitis C, and hepatitis B in this population?

Key concepts

• Blood-borne transmission
• People who inject drugs
• HIV infection
• Hepatitis C and hepatitis B
• Injection risk behaviour
• Structural and combination prevention
• Risk environment

Mechanisms

Sharing of needles, syringes, and injecting equipment provides a direct route for blood-borne viruses to pass between people, driving transmission of HIV, hepatitis C, and hepatitis B (Nelson, 2011). Transmission is shaped not only by individual behaviour but by structural conditions, the risk environment, that influence access to sterile equipment and exposure to risk; prevention therefore combines individual, structural, and biomedical approaches (Degenhardt, 2010).

Clinical relevance

Understanding why substance use, especially injection, is tied to blood-borne infection is central to appraising the medical complications of addiction and the rationale for prevention. This entry describes that relationship; it does not provide individualised testing, prophylaxis, or treatment direction, which belong to current infectious-disease and addiction guidelines.

Epidemiology

People who inject drugs carry a high global burden of viral hepatitis, with substantial proportions exposed to hepatitis C and hepatitis B across many regions (Nelson, 2011). HIV prevalence among people who inject drugs is also elevated in many settings, and combinations of prevention measures are associated with reduced transmission (Degenhardt, 2010).

Evidence & guidelines

Evidence in this topic includes systematic reviews quantifying global hepatitis burden among people who inject drugs (Nelson, 2011) and reviews of HIV prevention strategy (Degenhardt, 2010). Testing, prophylaxis, and treatment recommendations belong to infectious-disease and harm-reduction guidelines rather than to this reference entry.

History

The HIV epidemic of the 1980s drew sharp attention to injection drug use as a route of blood-borne transmission, catalysing harm-reduction approaches such as sterile-equipment provision. Subsequent global syntheses quantified the burden of HIV and viral hepatitis among people who inject drugs and framed prevention as requiring combined individual and structural action (Degenhardt, 2010; Nelson, 2011).

Debates

Individual versus structural drivers of transmission

Effective prevention is argued to require attention beyond individual behaviour to the structural risk environment and to combinations of measures, a framing that informs harm-reduction policy debates.

Key figures

• Louisa Degenhardt
• Paul Nelson
• Bradley Mathers

Seminal works

• degenhardt-2010
• nelson-2011

Frequently asked questions

Why are HIV and hepatitis linked to injection drug use?

Sharing needles and injecting equipment provides a direct route for blood-borne viruses to pass between people, making HIV and viral hepatitis major complications of injection drug use.

Is prevention only about individual behaviour?

No. Evidence indicates that reducing transmission requires combining individual, biomedical, and structural measures that shape the broader risk environment.